Summary Recombinant interleukin 2 (rIL-2) and flavone acetic acid (FAA) 
Interleukin-2 (IL-2) is the principal component of the T cell growth factor (Morgan et al., 1976) . Lymphokine activated killer (LAK) cells can be are generated by the incubation of human peripheral blood lymphocytes with IL-2. These cells are capable of lysing fresh, natural killer (NK) cell resistant, tumour cells but not normal cells (Grimm et al., 1982) . High dose rIL-2 either alone or in combination with LAK cells has now been used to treat a number of patients with advanced cancer resistant to conventional therapies, resulting in impressive tumour responses (Rosenberg et al., 1987) . A recent update indicates that some of these patients are alive 3 years or more following treatment (Rosenberg et al., 1989) . However, the treatment was associated with serious side-effects which on occasions required intensive care facilities. Nevertheless, there were five partial remissions in 16 patients with advanced melanoma. There are considerable logistic difficulties in generating the LAK cells which require repeated leucophereses followed by rIL-2 in vitro incubation and re-infusion of the cultured cells. In our previous phase I/II study using rIL-2 intrasplenically and intravenously, there were four partial responses (although in only one did all disease sites respond) and eight patients with stable disease out of a total of 31 patients with previously progressing advanced melanoma. Five patients remain alive at 10-16 months (Thatcher et al., 1989a) . The intrasplenic route was used to try and generate LAK cells in vivo rather than employing the cumbersome in vitro technique, high dose rIL-2 was then administered intravenously on alternate days without major toxicity.
New approaches for the treatment of advanced melanoma are urgently needed, given the rapid increase in incident of this tumour and the poor impact of chemotherapy even at high dose (Thatcher et al., 1989b) . The observation that flavone acetic acid (FAA) enhances organ associated NK cell activity, including activity within the spleen, was therefore of interest (Ching & Baguley, 1987; Hornung et al., 1988; Wiltrout et al., 1988) . FAA and rIL-2 together were found to be curative in mouse renal cancer whereas either agent alone was ineffective (Wiltrout et al., 1988) . FAA, a synthetic flavonoid, is known also to have unexpectedly high activity against a variety of murine tumours including melanoma (Plowman et al., 1986; O'Dwyer et al., 1987 (Kerr et al., 1987; Weiss et al., 1988) and NK activity in human blood has been enhanced by FAA . Other features of FAA which are of advantage clinically include the lack of alopecia and myelosuppression although hypotension and lethargy are the dose limiting toxicities (Kerr et al., 1987; Weiss et al., 1988) .
Given the alternate day administration schedule of our previous rIL-2 study, and the experimental, immunogical and clinical data for FAA, it was considered reasonable to combine both agents. The NK activity was known to peak at about 24 h after FAA in the murine renal cell model (Wiltrout et al., 1988) and there were significant increases in NK activity by 24 h in three of six patients examined by Urba et al. (1988) . The maximum tolerated dose in our previous alternate day rIL-2 study was 10.9 x 106 Cetus units m2. Maximum tolerated doses determined for FAA depended on the administration schedule, i.e. 6.4 G m2 given i.v. over I h or 3 h every week for a minimum of 3 weeks or up to 10 G m-2 when infused over 6 h (Kerr et al., 1987; Table I ; only five patients had solely non-visceral disease ie metastases limited to skin, superficial soft tissues and peripheral lymph nodes.
Interleukin-2
The rIL-2 was kindly supplied by Eurocetus Corporation, Amsterdam, and the administration over 1 h has been described previously (Thatcher et al., 1989a) . Briefly, the first rIL-2 dose was given via a catheter (femoral approach) positioned in the splenic artery, four hours later a further dose was given intravenously by three alternate day i.v. doses. A complete treatment course therefore involved five rIL-2 administrations over a 6 day period. The day before each rIL-2 administration, FAA (kindly supplied by Lipha, Lyon) at a dose of 4.8 G m-2 with light protection was given as a 6 h i.v. infusion. Four FAA infusions per course were given. Alkalinisation of urine was used to prevent possible renal damage by FAA by giving 500 ml 1.26% sodium bicarbonate i.v. over 1 h before and after the FAA infusion the latter being given in 500 ml normal saline. Treatment was repeated for a maximum of three courses at 21-day intervals from the start of the FAA.
Supportive care Pyrexia was controlled with paracetamol and no anti inflammatory agents were used. Moderate to severe blood pressure changes (grade 3) were treated conservatively by stopping any infusion and when required by the addition of normal saline over 30-40 min. No specialised monitoring was undertaken and patients were treated on a general medical oncology ward. Regular recording of the patient's general status and vital signs while on treatment were performed as previously (Thatcher et al., 1989a) . Following relapse or progression DTIC 250 mg m-2 i.v. daily for 5 days with melphalan 15mg m2 i.v on day 3 or other palliative therapy was considered.
Response toxicity evaluation andfollow-up Response and toxicity was evaluated by using standard WHO criteria. Stable disease followed the definition of 'no change', i.e. no significant change for at least 4 weeks, estimated decrease of less than 50%, and lesions with estimated increase of less than 25% (Miller et al., 1981) . The time of onset and duration of any side efects were also recorded and when possible ascribed to either a rIL-2 or 1.9 1.8 1.9 1.7 1.9 1.5 1.5 1.9 1.7 1.5 1.6 2.0 2.0 1.8 1.8 1.7 1.6 1.6 1.9 1.8 1.9 2.0 2.1 1.7 1.8 1.7 1.8 1.9 1.7 1.9 1.8 2.0 1.9 1.9
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FAA administration. Hypotension and hypertension was scored as indicated in the results section. Blood counts and biochemistry were performed at the start of treatment and weekly between courses. The performance score was also assessed before and after treatment (Miller et al., 1981) . Follow-up visits following completion of the protocol were at 4-6 week intervals for the first 6 months and every 2-3 months thereafter.
Results

Response
In the study group of 34 patients there was one patient with complete response (3%), which occurred in both peripheral lymph nodes an hepatic metastases (confirmed on CT scan).
In four other patients partial response (12%) occurred. Responses occurred predominantly in non-visceral metastases, i.e. nodes, skin and soft tissue, although lung metastases also responded. The majority of these responses were noted after the second course. Seven other patients showed response in one or more sites, particularly soft tissue areas but with progression or stable disease elsewhere (see Table I ). Three patients (out of 12) who received chemotherapy with DTIC and melphalan had a partial response (see Table I ). The lymphocyte count was also examined in those patients who did not progress (44%: five patients who responded and 10 with stable disease) and the 19 patients (56%) in which progression occurred during treatment. There were no obvious differences between the median lymphocyte values between these two patient groups, but there was considerable change in the lymphocyte count with treatment ( Figure 1 ). There were no significantly differences between the lymphocyte counts on day 0, 21 and 42, i.e. immediately before a rIL-2 course, and the counts 14 days later (Wilcoxon matched pairs signed ranks test, two-tailed P >0.260). The median survival of all 34 patients is 4 months with a range of 1-17 months. Eleven patients remain alive at 6-17 months and in five of these patients there is no relapse or progression of disease (see Table I ). leucopenia but had marrow metastases. There were two patients with 10-fold increases in the AST level; again these abnormalities were transient. There were no other major problems occurring in the haematological or biochemical parameters (see Table II ). In particular renal function was mildly and transiently impaired on only eight occasions and there was no weight gain of 5% or more. The other toxicities are shown in Table II . There were four episodes of severe dyspnoea occurring at rest soon after rIL-2 administration, and the severe neurotoxicity which occurred on five occasions was again mainly a feature of rIL-2 and was transient. Arthalgia and myalgia was reported on direct questioning on 27 courses. In five patients there was a rapid development of a dry, itchy, desquamating rash lasting for up to 10 days. These symptoms were not clearly associated with the marked eosinophilia (>20% of the total WBC) which occurred on 16 courses. No patient developed positive auto-antibodies although screening was not performed in every patient. Other side-effects, i.e. gastrointestinal, fever and so forth, were either absent or mild on the large majority of courses (see Table II ). The most worrying toxicity concerned blood pressures changes, which were of a severe grade on 17 occasions. The main problem was hypotension with the FAA administration (see Table II ). However, this severe grade of blood pressure change lasted for less than half an hour although there was perturbation of some degree for several hours. The duration of side-effects was generally very short but in the occasional patient lasted a day or more. In most cases, side-effects occurred within 2-3 h of starting rIL-2 or FAA, although the onset of diarrhoea and neurotoxicity was somewhat longer (4-5 h) and the ventricular tachycardia started 8 h after the rIL-2 treatment. The duration of side-effects after either the rIL-2 or FAA was generally quite short and only fever (of a mild degree) persisted for a median duration of more than 12 hours. The patients' major complaints were of myalgia and a general feeling of lethargy which persisted during the week of treatment. There was no evidence of worsening toxicity with subsequent courses although there was the impression that the patients became more lethargic throughout the week of treatment, particularly on the second and third courses. There was one episode of transient lower limb embolism associated with splenic artery catheterisation. In two patients (numbers 20 and 32) catheterisation was not technically possible and the rIL-2 dose was given intravenously.
The performance score was also assessed before and immediately at the end of the week's therapy and again just before the next course. The treatment itself did not appear to impair performance status. The Karnofsky scores were compared before treatment and at 1 month after treatment. Patients who died were included and scored as zero. The score was unchanged in 12 patients but did decrease in a further 12, whereas in the remaining 10 the score increased by at least two levels and four patients returned to completely normal activity.
Discussion
The current study of rIL-2 and FAA in metastatic melanoma is the first report of this experimentally attractive combination. The current study immediately followed our previous investigation which used rIL-2 alone (Thatcher et al., 1989a) . The addition of FAA did not require lower rIL-2 doses to be used. Indeed, the median cumulative dose of rIL-2 in the present study with FAA was 12.0 x 107 U m-2 (range 33-165) with 9% of doses being omitted because of toxicity. These values are very similar to the preceding phase II, rIL-2 alone study, with a cumulative dose of 14.0 x 107 U m2 (range 1-165) and 11% of doses omitted, although these data were only from 16 patients. These median cumulative doses of rIL-2 are comparable to the dose given per patient in Rosenberg's series (8-9 x 107 U m-2), although the dose was administered over a median of one course rather than two in our studies (Rosenberg et al., 1987) . In this study it was not possible to determine the influence of the intrasplenic dose on the patients' disease activity or on lymphocyte count. The two patients who did not receive intrasplenic doses are alive at 6 and 17 months. There was no marked increase in toxicity following the addition of FAA and again no intensive care facilities were required. Despite the potential for aggravation of common side-effects, i.e. blood pressure, there was no major increase in grade 3 hypotension (20%) with FAA and rIL-2 versus 17% with rIL-2 alone in our previous study (Thatcher et al., 1989a) . However, hypertension of grade 3 severity was noted on 8% of courses with the combination, and 9% with rIL-2 alone but of lower grade. Again, severe dyspnoea did not increase with the addition of FAA but there did appear to be an increase in myalgia and arthralgia (81% of courses with the FAA, rIL-2 combination) compared with 61% with rIL-2 alone. This side-effect was the most troublesome for the majority of patients and was only partly controlled with paracetamol.
Fifty-six per cent of patients with FAA were progressers compared with 61% in the previous rIL-2 alone study. There were, however, more responders (15%), including one complete response (Thatcher et al., 1989a) . Another feature of both studies was the number of patients whose disease was progressing before treatment, but stabilised at least in some patients for many months. No statistically significant differences in the lymphocyte count or other immunological parameters between progressers and non-progressers were noted in this study or previously (Ghosh et al., 1989) . Other investigators (West et al., 1987) have suggested that marked 'overshoot' in the lymphocyte count with rIL-2 treatment is associated with tumour response.
The addition of FAA to rIL-2 did not produce any marked improvement despite the encouraging animal studies. However, the combination did not increase toxicity over that reported with rIL-2 alone and no patient required intensive care facilities. Further studies using rIL-2 in combination with other biological response modifiers, e.g. interferon and tumour necrosis factor, and with chemotherapeutic agents, such as DTIC, in malignant melanoma require further exploration.
